Connect your AI

Opus Genetics IRD Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

BridgeBio PharmaBBIO

——

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's convertible preferred stock outstanding shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's convertible preferred stock outstanding shares?: Opus Genetics (IRD) reported convertible preferred stock outstanding shares of 0 in Q1 2026.